|
HLB is a South Korean diversified manufacturer operating in healthcare, biotechnology, and marine equipment. The company is organized into three main business segments: healthcare, biotechnology, and shipbuilding. In healthcare, HLB manufactures and sells in-vitro diagnostic medical devices, such as specimen collection kits and blood glucose monitors, along with pharmaceutical quasi-drugs like alcohol swabs and disinfectants, and cosmetic products. Its biotechnology segment focuses on the development of targeted cancer therapies, including the oral tyrosine kinase inhibitor Rivoceranib for hepatocellular carcinoma and the licensed-in drug lirafugatinib for cholangiocarcinoma. The shipbuilding segment designs and builds special-purpose vessels, including patrol boats and leisure craft, and manufactures lifeboats, davits, and GRP/GRE pipes for ballast and scrubber systems. HLB serves domestic and international pharmaceutical companies, diagnostic device manufacturers, government agencies, coast guards, navies, and shipyards. The company was founded in 1975, originally as a lifeboat manufacturer, and has since expanded into global pharmaceutical and biotechnology development. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Drug Manufacturers - General | Homepage hlbbio.co.kr |
| Sector Healthcare | IR page hlbbio.co.kr/ir/financial/disclosure | |
|
Tags
in-vitro diagnostics, targeted cancer therapy, hepatocellular carcinoma, cholangiocarcinoma, special-purpose vessels, lifeboats, grp pipes, pharmaceutical quasi-drugs, biotechnology, marine equipment, Rivoceranib, lirafugatinib, Elevar Therapeutics, Immunomic Therapeutics, Verismo Therapeutics, HLB ENG, HLB Healthcare, HLB Bio
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | — |
| Market cap (USD) | — |
| P/E | — |
| PEG | — |
| P/BV | — |
| P/S | — |
| P/OCF | — |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -44.3% |
| ROI | -52.7% |
| ROIC | -18.7% |
| Profit margin | -262.0% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | Yes |
| Buying back stock | — |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | -50.0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 84.173B | 68.126B | 42.901B | 179.708B | 69.826B | 56.177B | 38.421B | 36.186B | 23.007B | 30.139B | 38.461B | 37.186B | 31.452B |
| Net profit | -220.501B | -91.98B | -189.079B | -76.668B | -98.125B | -80.093B | -44.386B | 25.343B | -16.53B | -13.215B | 12.64B | -2.931B | -8.545B |
| Free cash flow | -109.535B | -134.281B | -117.501B | -73.551B | -56.952B | -57.486B | -50.376B | -21.189B | -20.784B | -11.783B | -2.007B | -5.635B | -4.853B |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 2.93B | 3.24B | 6.53B | 6.58B | 11.7B | 34B | 15.1B | 7.23B | 8.92B | 9.52B |
| ↳ YoY growth | -39.0% | +10.7% | +101.4% | +0.8% | +78.4% | +189.7% | -55.5% | -52.3% | +23.4% | +6.7% |
| ↳ 5y CAGR | +2.9% | -3.8% | +19.6% | +63.3% | +36.1% | +2.0% | +6.3% | -4.1% | ||
| Borrowings, current (KRW) | 7.33B | 31.5B | 11B | 12.1B | 44B | 21.2B | 115B | 28.7B | 99.4B | 207B |
| Borrowings, non-current (KRW) | 6.06B | 4.32B | 31.6B | 74.5B | 614M | 47.4B | 320M | 17.9B | 44.4B | 58.2B |
| Lease liabilities (KRW) | — | — | — | — | — | — | 14.3B | 16B | 16.3B | 19.7B |
| Cash and deposits (KRW) | 9.37B | 7.35B | 30.2B | 40.9B | 221B | 99.8B | 196B | 109B | 93B | 41B |
| Intangible assets (KRW) | 131B | 127B | 134B | 134B | 264B | 340B | 345B | 269B | 312B | 334B |
| Right-of-use assets (KRW) | — | — | — | — | — | 9.47B | 12.6B | 11.3B | 11.1B | 14.7B |
| Net debt (borrowings + leases - cash) (KRW) | -3.31B | 28.5B | 12.3B | 45.8B | -176B | -31.2B | -80.2B | -62.3B | 67B | 244B |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | -10.2B | -19.1B | -20.7B | -48.7B | -56.5B | -54.8B | -61.8B | -112B | -114B | -92.6B |
| Purchases of property, plant and equipment (KRW) | -1.63B | -1.7B | -517M | -1.72B | -972M | -2.19B | -11.7B | -5.87B | -20B | -16.9B |
| Purchases of intangible assets (KRW) | -789M | -364M | -78.5M | -163M | -74B | -3.95B | -893M | -1.19B | -7.1B | -586M |
| Dividends paid (cash effect) (KRW) | — | — | 0.00 | 0.00 | -83.6M | — | — | — | — | — |
| Share buybacks (cash effect) (KRW) | — | — | 0.00 | 0.00 | -3.81B | 0.00 | 0.00 | -4.08B | 0.00 | 0.00 |
| Interest paid (cash effect) (KRW) | -242M | -228M | -441M | -2.47B | -326M | -217M | -350M | -1.29B | -2.1B | -3.27B |
| Income taxes paid (cash effect) (KRW) | 77.6M | 3.28M | -16.8M | -68.9M | -120M | 7.8B | -5.7B | -5.8B | 197M | 5.93B |
| Free cash flow (OCF - PPE - intangibles) (KRW) | -12.6B | -21.1B | -21.3B | -50.5B | -131B | -60.9B | -74.4B | -119B | -141B | -110B |
| Income detail | ||||||||||
| Total comprehensive income (KRW) | -22.9B | -23.9B | 18.7B | -51.8B | -104B | -86.3B | -77.2B | -200B | -65.2B | -244B |
| Comprehensive income to owners (KRW) | -13.2B | -17.8B | 29B | -38.8B | -95.3B | -75.4B | -60.6B | -184B | -54.1B | -228B |
| Reported | Nov 14, 2017 | Mar 30, 2018 | Mar 22, 2021 | Mar 22, 2021 | Mar 22, 2021 | Mar 21, 2024 | Mar 21, 2025 | Mar 21, 2025 | Mar 21, 2025 | Mar 23, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding HLB
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| NTSE | 0.03% | 570 | $ 19.131K | Jun 30, 2026 |
| DFSE | 0.01% | 3,367 | $ 74.403K | Nov 12, 2026 |
| DFAE | 0.01% | 28,293 | $ 625.213K | Nov 12, 2026 |
| DEXC | 0.01% | 629 | $ 13.9K | Nov 12, 2026 |
| DFEM | 0.00% | 11,120 | $ 245.727K | Nov 12, 2026 |
| DFAX | 0.00% | 6,248 | $ 138.067K | Nov 12, 2026 |
| AVEM | 0.00% | 1 | $ 20.79 | Nov 16, 2026 |